| Literature DB >> 23739610 |
Y G Chen1, J P Mordes, E P Blankenhorn, H Kashmiri, M L Kaldunski, S Jia, R Geoffrey, X Wang, M J Hessner.
Abstract
The dilute plasma cytokine milieu associated with type 1 diabetes (T1D), while difficult to measure directly, is sufficient to drive transcription in a bioassay that uses healthy leukocytes as reporters. Previously, we reported disease-associated, partially IL-1 dependent, transcriptional signatures in both T1D patients and the BioBreeding (BB) rat model. Here, we examine temporal signatures in congenic BBDR.lyp/lyp rats that develop spontaneous T1D, and BBDR rats where T1D progresses only after immunological perturbation in young animals. After weaning, the BBDR temporal signature showed early coincident induction of transcription related to innate inflammation as well as IL-10- and TGF-β-mediated regulation. BBDR plasma cytokine levels mirrored the signatures showing early inflammation, followed by induction of a regulated state that correlated with failure of virus to induce T1D in older rats. In contrast, the BBDR.lyp/lyp temporal signature exhibited asynchronous dynamics, with delayed induction of inflammatory transcription and later, weaker induction of regulatory transcription, consistent with their deficiency in regulatory T cells. Through longitudinal analyses of plasma-induced signatures in BB rats and a human T1D progressor, we have identified changes in immunoregulatory processes that attenuate a preexisting innate inflammatory state in BBDR rats, suggesting a mechanism underlying the decline in T1D susceptibility with age.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23739610 PMCID: PMC4027975 DOI: 10.1038/gene.2013.31
Source DB: PubMed Journal: Genes Immun ISSN: 1466-4879 Impact factor: 2.676
Figure 1Transcriptional signatures induced by plasma longitudinally collected from BBDR and BBDR.lyp/lyp rats. A. Study design: responder PBMCs of three BN rats were each cultured under 10 different conditions: autologous serum (n = 3 cultures); allogeneic BN serum (n = 9 cultures); day 30, day 40, day 50 and day 60 BBDR.lyp/lyp serum pools (n = 3 cultures each), day 30, day 40, day 50 and day 60 BBDR serum pools (n = 3 cultures each). The serum pools were each created from an equal contribution of six individual, normoglycemic rats. Gene expression was measured independently in each culture, and all data were normalized with that of the autologous induction. B. Significantly regulated model profiles identified by the S.T.E.M. software. C. A Venn diagram and one-way hierarchical clustering (probe sets only) illustrating the relationship between the probe sets temporally regulated by BBDR.lyp/lyp and BBDR plasma (profiles 7 and 0 combined). Expression levels illustrated in the heat maps are normalized against the mean of day 30 BBDR and day 30 BBDR.lyp/lyp. D. Relationship between the regulated probe sets identified by S.T.E.M. analysis of BBDR.lyp/lyp and BBDR longitudinal plasma induced profiles compared to those previously identified when directly comparing samples collected from day 60 BBDR and day 60 BBDR.lyp/lyp rats[18].
Significantly regulated pathways identified by STEM analysis
| BBDR. | BBDR | BBDR. | BBDR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | Category Name | Genes | p-value | Genes | p-value | Genes | p-value | Genes | p-value |
| GO:0001664 | G-protein coupled receptor binding | 5 | 8.9E-03 | n.s | n.s | n.s | |||
| GO:0001819 | positive regulation of cytokine production | 8 | 4.9E-04 | 6 | 2.6E-03 | n.s | n.s | ||
| GO:0002237 | response to molecule of bacterial origin | 14 | 5.0E-04 | 15 | 5.8E-03 | n.s | n.s | ||
| GO:0002366 | leukocyte activation involved in immune response | 5 | 6.5E-04 | n.s | n.s | n.s | |||
| GO:0002685 | regulation of leukocyte migration | n.s | 5 | 4.8E-04 | n.s | n.s | |||
| GO:0002697 | regulation of immune effector process | n.s | 5 | 1.0E-02 | n.s | n.s | |||
| GO:0002764 | immune response-regulating signaling pathway | n.s | 7 | 1.4E-03 | 5 | 6.7E-03 | n.s | ||
| GO:0005125 | cytokine activity | 6 | 1.8E-04 | n.s | n.s | n.s | |||
| GO:0005126 | cytokine receptor binding | 7 | 1.1E-04 | n.s | n.s | n.s | |||
| GO:0006954 | inflammatory response | 14 | 3.6E-06 | 13 | 2.0E-05 | n.s | n.s | ||
| GO:0007155 | cell adhesion | 14 | 1.0E-02 | 14 | 1.6E-03 | n.s | 9 | 1.0E-02 | |
| GO:0007162 | negative regulation of cell adhesion | n.s | 5 | 2.1E-04 | n.s | n.s | |||
| GO:0030593 | neutrophil chemotaxis | 5 | 4.3E-06 | n.s | n.s | n.s | |||
| GO:0043405 | regulation of MAP kinase activity | 7 | 2.1E-04 | n.s | n.s | n.s | |||
| GO:0045087 | innate immune response | 10 | 2.2E-03 | 15 | 4.7E-03 | 7 | 7.1E-03 | n.s | |
| GO:0045321 | leukocyte activation | 8 | 5.3E-03 | 15 | 2.9E-04 | n.s | n.s | ||
| GO:0050727 | regulation of inflammatory response | n.s | 6 | 2.5E-03 | n.s | n.s | |||
| GO:0050776 | regulation of immune response | 10 | 1.0E-02 | 12 | 8.1E-05 | 12 | 1.2E-03 | n.s | |
| GO:0050778 | positive regulation of immune response | 5 | 1.0E-02 | 10 | 2.1E-05 | 9 | 6.7E-03 | n.s | |
| GO:0080134 | regulation of response to stress | n.s | 11 | 4.5E-03 | n.s | n.s | |||
Not Significant
Figure 2Analysis of BBDR.lyp/lyp and BBDR S.T.E.M. Profiles 7 and 0. Panels A and B: Venn diagrams and one-way hierarchical clustering (probe sets only) illustrating the relationship between the probe sets temporally regulated by BBDR.lyp/lyp and BBDR plasma belonging to S.T.E.M. profiles 7 and profiles 0, respectively. Panels C and D. Expression levels of well annotated probe sets temporally regulated by BBDR.lyp/lyp and BBDR plasma belonging to S.T.E.M. profiles 7 and profiles 0, respectively. In panels A–D heat maps (and font colors) correspond to the three subsets defined by each Venn diagram. Expression levels illustrated in the heat maps are normalized against the mean of day 30 BBDR and day 30 BBDR.lyp/lyp.
Cytokine/chemokine levels (pg/ml) in BBDR.lyp/lyp, BBDR, and BN rats
| Cytokine | Day 30 | Day 40 | Day 50 | Day 60 | Day 30 | Day 40 | Day 50 | Day 60 | Day 180 | Lower |
|---|---|---|---|---|---|---|---|---|---|---|
| IL-1α | 7.2±6.1 | 9.3±7.0 | 0 | 0 | 53.7±41.9 | 31.6±24.2 | 6.9±5.5 | 0 | 0 | >27 |
| IL-1β | 17.4±4.1 | 12.6±2.6 | 9.5±3.9 | 15.6±4.4 | 9.7±5.2 | 30.5±13.4 | 21.4±6.6 | 11.7±6.0 | 11.8±8.1 | >27 |
| IL-2 | 20.2±7.4 | 73.1±37.9 | 26.8±8.9 | 20.7±6.9 | 69.1±40.9 | 29.7±9.4 | 23.8±9.7 | 3.9±3.9 | >75 | |
| IL-4 | 22.3±4.5 | 8.0±2.1 | 1.9±1.9 | 16.9±6.5 | 5.1±3.9 | 6.7±3.3 | >27 | |||
| IL-5 | 0.3±0.3 | 0 | 0 | 19.6±10.8 | 0.9±0.9 | 0.3±0.3 | 0 | 0 | 0 | >10 |
| IL-6 | 32.6±23.4 | 0 | 0 | 1.6±1.3 | 107.2±95.0 | 115.2±93.2 | 6.3±6.3 | 0 | 1.8±1.8 | >250 |
| IL-9 | 206.7±53.2 | 192.9±74.3 | 149.0±64.5 | 224.1±43.9 | 373.6±173.2 | 238.0±85.7 | 214.2±10.0 | 105.0±28.5 | 102.9±55.8 | >250 |
| IL-10 | 85.4±17.7 | 47.7±12.2 | 62.2±22.4 | 107.2±29.9 | 48.4±13.9 | 111.4±60.4 | 101.6±30.1 | 58.2±19.4 | 42.7±24.2 | >27 |
| IL-13 | 28.2±13.0 | 65.3±35.5 | 31.0±14.6 | 30.3±5.0 | 14.1±2.2 | 14.1±4.4 | >27 | |||
| IL-17 | 5.2±3.4 | 1.1±0.5 | 0 | 0 | 21.4±13.9 | 7.8±3.7 | 0.3±0.2 | 0 | 0 | >10 |
| IL-18 | 3.2±1.6 | >10 | ||||||||
| G-CSF | 3.4±3.4 | 0.2±0.2 | 0 | 0 | 10.7±10.2 | 3.3±3.3 | 0 | 0 | 0 | >10 |
| GM-CSF | 9.5±6.3 | 3.8±3.8 | 7.9±3.8 | 6.9±5.2 | 33.9±29.1 | 17.7±8.5 | 8.1±1.6 | 0 | 2.9±2.9 | >27 |
| CXCL1 | 303.5±57.4 | 302.5±45.0 | 315.3±45.9 | 245.6±25.4 | 199.8±34.7 | >27 | ||||
| Eotaxin | 16.9±2.7 | 18.8±2.8 | 2.2±1.4 | 0.9±0.9 | 23.0±6.7 | 7.7±4.4 | 0 | 8.4±2.8 | >27 | |
| IFN-γ | 20.2±14.1 | 33.4±14.3 | 5.6±2.7 | 3.9±2.3 | 98.7±67.5 | 63.6±43.7 | 1.6±1.0 | 0 | >27 | |
| IP-10 | 5.2±3.4 | 3.4±1.9 | 0.1±0.1 | 0 | 17.0±11.9 | 12.0±9.1 | 4.7±2.7 | 0 | 0.2±0.2 | >10 |
| Leptin | 1000.3±384.4 | 1588.8±189.9 | 1470.6±421.0 | 1727.4±607.1 | 1626.5±374.2 | 2104.9±504.1 | 2461.3±578.4 | 2478.8±602.3 | 1438.4±203.9 | >10 |
| CCL2 | 69.3±22.1 | 70.8±13.9 | 70.4±27.4 | 80.0±33.0 | 124.9±27.2 | 79.8±14.5 | 54.8±18.8 | 45.8±21.1 | 87.6±7.3 | >75 |
| MIP-1α | 0 | 0 | 0.1±0.1 | 0 | 0 | 10.6±8.1 | 0 | 0 | 0 | >10 |
| Rantes | 5649.2±2984.1 | 1496.9±416.0 | 9946.4±3710.4 | 3926.1±2134.3 | 9449.8±7031.8 | 6757.0±4493.9 | 1530.2±176.7 | >27 | ||
| TNF-α | 1.2±0.8 | 0.5±0.5 | 1.5±0.8 | 1.6±0.9 | 13.5±12.7 | 2.1±1.9 | 3.5±2.2 | 0 | 16.9±3.1 | >10 |
| VEGF | 0 | 0.1±0.1 | 0 | 0 | 0.1±0.1 | 0.6±0.6 | 0 | 0 | 0 | >27 |
| IL-12p70 | 11.4±6.5 | 5.8±4.5 | 0 | 0 | 12.9±7.8 | 23.8±12.5 | 10.5±8.1 | 0 | 0 | >27 |
| TGF-β | 6788.2±838.9 | 5351.0±538.5 | 6073.4±769.2 | 7416.1±2728.6 | 9406.9±2079.4 | 6283.0±1246.6 | 6959.1±899.8 | 6506.1±3122.2 | >1.9 |
G-CSF, Granulocyte colony-stimulating factor.
GM-CSF, Granulocyte/macrophage colony-stimulating factor.
CXCL1, Growth-regulated oncogene alpha, chemokine.
CCL2, Monocyte chemoattractant protein.
MIP-1α, Macrophage inflammatory protein-1α.
VEGF, Vascular endothelial growth factor.
Data are means ± SE of six rats per group (pg/ml). Each sample was tested in duplicate using the Millipore BeadLyte cytokine assay kit, except for TGF-β. Significant differences for mean cytokine levels meeting detection thresholds are indicated:
P <0.01 Wilcoxon rank-sum test versus BN;
P <0.05 Wilcoxon rank-sum test versus BN;
P<0.01 Wilcoxon rank-sum test BBDR.lyp/lyp versus BBDR at same time point;
P< 0.05 Wilcoxon rank-sum test BBDR.lyp/lyp or BBDR versus intra-strain Day 30.
Figure 3Heat map representing mean concentrations of individual cytokines in longitudinally collected plasmas of BBDR.lyp/lyp and BBDR rats. Color representation (green to red) for each individual cytokine reflects the normalized ratio between the concentration measured at given strain/time-point relative to the mean concentration of all strains/time-points. Yellow triangles denote p< 0.05 Wilcoxon rank-sum test BBDR.lyp/lyp or BBDR versus intra-strain day 30.
Figure 4Investigation of IL-10 and TGF-β as ligands associated with the BBDR temporal signature. PBMCs of seven BN rats each were cultured under four different conditions: 1) day 30 BBDR plasma pool (n = 7 cultures); 2) day 30 BBDR plasma supplemented with 20 ng/ml TGF-β (n = 7 cultures); 3) day 30 BBDR plasma supplemented with 50 ng/ml IL-10 (n = 7 cultures); 4) day 30 BBDR plasma supplemented with 50 ng/ml IL-10 and 20 ng/ml TGF-β (n = 7 cultures). The plasma pools were created from an equal contribution of six normoglycemic rats independent of those used in the microarray-based signature studies. Gene expression was measured independently, in duplicate, for each culture by qRT-PCR and normalized against the abundance of 18s rRNA. Data is expressed relative to day 30 expression levels for each gene. *p<0.05, ANOVA, relative to day 30.
Penetrance of T1D in BBDR rats treated with Poly I:C or viral infection at different ages
| KRV (107 PFU) | Poly I:C x3, followed by KRV | ||
|---|---|---|---|
| Age <30 days | Age >40 days | Age <30 days | Age >40 days |
| 40% (4/10) | 0% (0/6) | 100% (6/6) | 0% (0/6) |
Penetrance of T1D in BBDR rats treated with poly I:C alone (1 µg/gm on 3 consecutive days) or Kilham rat virus infection (107 PFU) alone, or KRV infection (107 PFU) given the day after poly I:C priming (1 µg/gm daily on 3 consecutive days) at different ages. Rats were followed until diabetes onset or day 40 after the start of treatment.
overall p<0.001 vs. <30 days group, Fisher exact statistic.
Figure 5Differential expression of Helios in Treg of BBDR.lyp/lyp and BBDR rats. Expression of Helios was analyzed in CD4+Foxp3+ Tregs from spleens (A) and pancreatic lymph nodes (B) of sex-matched 25, 40 or 60-day-old rats. Representative histograms of Helios expression (gated on CD4+Foxp3+ cells) of 60-day-old DP (solid line with shaded area) and DR (dotted line) rats are shown on the left. The right panels summarize the results from 3–4 rats per strain at each time point (mean±sem). *p < 0.05, ** p < 0.005, ***p < 0.0005, significantly different between BBDR.lyp/lyp and BBDR rats.
Figure 6Comparison of the BBDR.lyp/lyp longitudinal plasma-induced signature to that associated with human T1D progression. A. Venn diagram and one-way hierarchical clustering (genes only) for each component of the Venn diagram illustrating the relationship between the 360/914 functionally-related, direct orthologues induced plasma collected during human or BBDR.lyp/lyp rat T1D progression. Gene expression induced by longitudinally collected BBDR plasma is shown for comparison. B. One-way hierarchical clustering (genes only) of the 36 genes of the commonly regulated intersection. The 23 directionally concordant orthologues are bracketed. C. One-way hierarchical clustering (genes only) of selected genes among the 169 orthologous genes uniquely regulated by BBDR.lyp/lyp plasma. D. One-way hierarchical clustering (genes only) of selected genes among the 155 genes uniquely regulated by human longitudinal plasma. Genes significantly regulated by human recent onset T1D patients described in our seminal report[17] are indicated by *. Expression levels illustrated in the BB rat heat maps are normalized against the mean of day 30 BBDR and day 30 BBDR.lyp/lyp; expression levels illustrated in the human heat maps are normalized against the mean of all time points.
Figure 7Comparison of BBDR longitudinal plasma-induced signature to that associated to human T1D progression. A. One-way hierarchical clustering (genes only) for orthologous content between the rat and human arrays for genes belonging the BBDR profile 0 (n=139 genes, top panel) and profile 7 (n=159 genes, bottom panel). Gene expression induced by longitudinally collected BBDR.lyp/lyp plasma for these probe sets is shown for comparison. B. Expression levels of selected genes of the BBDR temporal signature. Among the 159 genes assigned to BBDR profile 7, 4 were ascribed to human profile 0: Fn1, Cbl, Klhl14, Bank1. Among the 139 genes assigned to BBDR profile 0, 11 were ascribed to human profile 7: Igfbp7, Fkbp5, Rasd1, Sytl3, F5, Ell2, Crim1, Ddit4, Tubb2a, Carm1, Rab5c. Expression levels illustrated in the BB rat heat maps are normalized against the mean of day 30 BBDR and day 30 BBDR.lyp/lyp; expression levels illustrated in the human heat maps are normalized against the mean of all time points.